Biohaven Pharmaceutical (NYSE:BHVN) Stock Rating Upgraded by Zacks Investment Research

Share on StockTwits

Biohaven Pharmaceutical (NYSE:BHVN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday, Zacks.com reports. The brokerage presently has a $47.00 price objective on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 9.07% from the stock’s current price.

According to Zacks, “Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company’s pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. “

Several other analysts also recently issued reports on the company. Canaccord Genuity restated an “average” rating on shares of Kellogg in a report on Tuesday, June 25th. Barclays set a $145.00 price objective on Sanderson Farms and gave the stock a “hold” rating in a report on Friday, May 31st. Needham & Company LLC cut their price objective on 2U to $75.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Goldman Sachs Group set a €75.30 ($87.56) price objective on Stroeer SE & Co KGaA and gave the stock a “buy” rating in a report on Monday, May 6th. Finally, Morgan Stanley set a $61.00 price objective on Walgreens Boots Alliance and gave the stock a “hold” rating in a report on Tuesday, May 14th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $70.18.

BHVN stock traded down $0.62 during trading on Tuesday, hitting $43.09. The company had a trading volume of 39,015 shares, compared to its average volume of 744,968. The company has a market capitalization of $1.92 billion, a price-to-earnings ratio of -7.01 and a beta of 0.26. The firm has a 50 day moving average price of $52.32. Biohaven Pharmaceutical has a fifty-two week low of $29.17 and a fifty-two week high of $67.86.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($1.41) earnings per share for the quarter, topping the consensus estimate of ($1.50) by $0.09. During the same quarter last year, the company posted ($2.32) earnings per share. Analysts anticipate that Biohaven Pharmaceutical will post -6.32 EPS for the current fiscal year.

In other Biohaven Pharmaceutical news, CEO Vlad Coric bought 5,000 shares of the stock in a transaction on Wednesday, June 26th. The shares were bought at an average price of $40.22 per share, with a total value of $201,100.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Declan Doogan sold 88,825 shares of Biohaven Pharmaceutical stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $58.42, for a total value of $5,189,156.50. Following the transaction, the director now directly owns 373,913 shares in the company, valued at approximately $21,843,997.46. The disclosure for this sale can be found here. In the last ninety days, insiders have acquired 17,500 shares of company stock worth $712,425. Company insiders own 23.90% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Blueshift Asset Management LLC bought a new stake in shares of Biohaven Pharmaceutical in the 4th quarter valued at approximately $306,000. EAM Global Investors LLC bought a new stake in shares of Biohaven Pharmaceutical in the 1st quarter valued at approximately $2,174,000. Pier Capital LLC bought a new stake in shares of Biohaven Pharmaceutical in the 1st quarter valued at approximately $3,541,000. Millennium Management LLC grew its stake in shares of Biohaven Pharmaceutical by 12.4% in the 4th quarter. Millennium Management LLC now owns 40,439 shares of the company’s stock valued at $1,495,000 after buying an additional 4,448 shares in the last quarter. Finally, Flinton Capital Management LLC bought a new stake in Biohaven Pharmaceutical during the fourth quarter worth approximately $42,000. 90.39% of the stock is owned by institutional investors and hedge funds.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Read More: What is dividend yield?

Get a free copy of the Zacks research report on Biohaven Pharmaceutical (BHVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Chromadex Corp  Expected to Announce Earnings of -$0.13 Per Share
Chromadex Corp Expected to Announce Earnings of -$0.13 Per Share
Groupon Inc  Short Interest Down 5.6% in June
Groupon Inc Short Interest Down 5.6% in June
nVent Electric PLC  to Issue Quarterly Dividend of $0.18 on  August 2nd
nVent Electric PLC to Issue Quarterly Dividend of $0.18 on August 2nd
Aquila Services Group PLC  To Go Ex-Dividend on July 18th
Aquila Services Group PLC To Go Ex-Dividend on July 18th
Dillard’s, Inc.  Short Interest Up 10.2% in June
Dillard’s, Inc. Short Interest Up 10.2% in June
Presidio Inc  Short Interest Up 10.6% in June
Presidio Inc Short Interest Up 10.6% in June


 
© 2006-2019 Zolmax.